Legacy & Industry Impact
An Early Innovator at a Defining Intersection
Angiotech is remembered as an early innovator at the intersection of pharmaceuticals, medical devices, and biomaterials. Our work helped demonstrate the commercial and clinical potential of drug-device combination technologies — an area that has since become an important segment of the medical technology industry.
Impact by the Numbers
Generation of drug-eluting cardiovascular stents enabled by our coating technology
Patients estimated to have received devices built on our platforms
Issued patents and pending filings across combination-product chemistry
Reducing Device-Related Complications
Our paclitaxel-coated devices demonstrated how pharmaceuticals could be integrated with implants to reduce complications such as tissue overgrowth — influencing later generations of combination medical technologies and shaping how the industry approaches implant safety today.
Cardiovascular Legacy
Our paclitaxel-coated devices helped define the modern drug-eluting stent category.
Biomaterials Foundation
Polymer and coating platforms now used across surgery, ophthalmology, and oncology.
Combination-Product Playbook
Design and regulatory patterns that influenced how the industry approaches drug-device products.
Continuing the Work
The categories we helped establish are still expanding. We continue to advance combination-product science across cardiovascular, oncology, ophthalmology, wound closure, and biomaterials.
Build on the Legacy
Bring your device program to a team that helped define the category.
Start a Conversation